# EDGAR Filing Document

**Accession Number:** 0001493137
**File Stem:** 0001553350-26-000075
**Filing Date:** 2026-5
**Character Count:** 78470
**Document Hash:** d1a19a103bae4f01f56b005658c8e5b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001553350-26-000075.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001553350-26-000075

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 48

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lifeloc Technologies, Inc
- **CENTRAL INDEX KEY:** 0001493137
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 841053680
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54319
- **FILM NUMBER:** 26979904

**BUSINESS ADDRESS:**
- **STREET 1:** 12441 WEST 49TH AVE UNIT #4
- **CITY:** WHEAT RIDGE
- **STATE:** CO
- **ZIP:** 80033
- **BUSINESS PHONE:** 303-431-9500

**MAIL ADDRESS:**
- **STREET 1:** 12441 WEST 49TH AVE UNIT #4
- **CITY:** WHEAT RIDGE
- **STATE:** CO
- **ZIP:** 80033

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lifeloc Technologies Inc
- **DATE OF NAME CHANGE:** 20100601

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Form 10-Q**

---

| | |
|:---|:---|
| **☒** | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | **For the quarterly period ended March 31, 2026** |

---

**OR**

---

| | |
|:---|:---|
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | **For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to** |

---

**Commission file number&nbsp;&nbsp;&nbsp;&nbsp; 000-54319**

**LIFELOC TECHNOLOGIES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Colorado** | **84-1053680** |
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) |
| incorporation or organization) |  |

---

**12441 West 49th Ave., Unit 4**

**Wheat Ridge, Colorado 80033**

(Address of principal executive offices)

**(303) 431-9500**

(Registrant's telephone number)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No **☐**

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit). Yes ☒&nbsp;&nbsp;&nbsp;&nbsp; No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☐ Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☐ <br> Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp; ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

---

| | |
|:---|:---|
| **Common Stock, no par value** | **2,752,616 Shares** |
| (Class) | (outstanding at March 31, 2026) |

---

**LIFELOC TECHNOLOGIES, INC.**

 **FORM 10-Q**

 **For the Three Months Ended March 31, 2026**

 **INDEX**

---

| | | |
|:---|:---|:---|
|  |  | &nbsp;&nbsp;**Page** |
|  |  | &nbsp;&nbsp;**Number** |
| &nbsp;&nbsp;**PART I.** | &nbsp;&nbsp;**[FINANCIAL INFORMATION](#a_001)** | &nbsp;&nbsp;3 |
| &nbsp;&nbsp; **ITEM 1** | &nbsp;&nbsp;**[FINANCIAL STATEMENTS (UNAUDITED)](#a_001)** |  |
|  | &nbsp;&nbsp;[Condensed Balance Sheets (Unaudited) as of March 31, 2026 and December 31, 2025](#a_001) | &nbsp;&nbsp;3 |
|  | &nbsp;&nbsp;[Condensed Statements of Profit (Loss) (Unaudited) for the three months ended March 31, 2026 and 2025](#a_002) | &nbsp;&nbsp;4 |
|  | &nbsp;&nbsp;[Statements of Changes in Stockholders' Equity (Unaudited) for the three months ended March 31, 2026 and 2025](#a_003) | &nbsp;&nbsp;5 |
|  | &nbsp;&nbsp;[Condensed Statements of Cash Flows (Unaudited) for the three months ended March 31, 2026 and 2025](#a_004) | &nbsp;&nbsp;6 |
|  | &nbsp;&nbsp;[Notes to Condensed Financial Statements (Unaudited)](#a_005) | &nbsp;&nbsp;7 |
| &nbsp;&nbsp; **ITEM 2** | &nbsp;&nbsp;**[MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_006)** | &nbsp;&nbsp;12 |
| &nbsp;&nbsp; **ITEM 3** | &nbsp;&nbsp;**[QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#a_007)** | &nbsp;&nbsp;16 |
| &nbsp;&nbsp; **ITEM 4** | &nbsp;&nbsp;**[CONTROLS AND PROCEDURES](#a_008)** | &nbsp;&nbsp;16 |
| &nbsp;&nbsp;**PART II.** | &nbsp;&nbsp;**[OTHER INFORMATION](#a_015)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 1** | &nbsp;&nbsp;**[LEGAL PROCEEDINGS](#a_010)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 1A** | &nbsp;&nbsp;**[RISK FACTORS](#a_011)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 2** | &nbsp;&nbsp;**[UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#a_012)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 3** | &nbsp;&nbsp;**[DEFAULTS UPON SENIOR SECURITIES](#a_013)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 4** | &nbsp;&nbsp;**[MINE SAFETY DISCLOSURES](#a_014)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 5** | &nbsp;&nbsp;**[OTHER INFORMATION](#a_015)** | &nbsp;&nbsp;17 |
| &nbsp;&nbsp; **ITEM 6** | &nbsp;&nbsp;**[EXHIBITS](#a_016)** | &nbsp;&nbsp;18 |
| &nbsp;&nbsp; **[SIGNATURES](#a_017)** | &nbsp;&nbsp; **[SIGNATURES](#a_017)** | &nbsp;&nbsp;19 |

---

**<u>PART I</u>&nbsp;&nbsp;&nbsp;&nbsp; <u>FINANCIAL INFORMATION</u>**

**ITEM 1 – FINANCIAL STATEMENTS**

**LIFELOC TECHNOLOGIES, INC.**

**Condensed Balance Sheets (Unaudited)**

---

| | | |
|:---|:---|:---|
| **ASSETS** | | |
| **CURRENT ASSETS:** |<br>**March 31, 2026** |<br>**December 31, 2025** |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $569330 | $746001 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 850341 | 772380 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 2794329 | 2633614 |
| &nbsp;&nbsp;&nbsp;Federal and state income taxes receivable | 55981 | 55981 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other | 99282 | 60825 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 4369263 | 4268801 |
| &nbsp;&nbsp;**PROPERTY, PLANT AND EQUIPMENT:** |  |  |
| &nbsp;&nbsp;&nbsp;Land | 317932 | 317932 |
| &nbsp;&nbsp;&nbsp;Building | 1928795 | 1928795 |
| &nbsp;&nbsp;&nbsp;Real-time Alcohol Detection And Recognition equipment and software | 569448 | 569448 |
| &nbsp;&nbsp;&nbsp;Production equipment, software and space modifications | 1366539 | 1366539 |
| &nbsp;&nbsp;&nbsp;Office equipment, software and space modifications | 197686 | 197686 |
| &nbsp;&nbsp;&nbsp;Sales and marketing equipment and space modifications | 230543 | 225173 |
| &nbsp;&nbsp;&nbsp;Research and development equipment, software and space modifications | 1232790 | 1213195 |
| &nbsp;&nbsp;&nbsp;Research and development equipment, software and space modifications not in service | 14411 | 19595 |
| &nbsp;&nbsp;&nbsp;Less accumulated depreciation | (3604323) | (3538455) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total property and equipment, net | 2253821 | 2299908 |
| &nbsp;&nbsp;**OTHER ASSETS:** |  |  |
| &nbsp;&nbsp;&nbsp;Patents, net | 69134 | 71039 |
| &nbsp;&nbsp;&nbsp;Deposits and other | 46820 | 46820 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total other assets | 115954 | 117859 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $6739038 | $6686568 |
| &nbsp;&nbsp;**<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>** |  |  |
| &nbsp;&nbsp;**CURRENT LIABILITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $615378 | $301627 |
| &nbsp;&nbsp;&nbsp;Term loan payable, current portion | 55271 | 54850 |
| &nbsp;&nbsp;&nbsp;Subordinated debentures payable, current portion | 34522 | 33371 |
| &nbsp;&nbsp;&nbsp;Customer and tenant deposits | 10692 | 25694 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 247670 | 321112 |
| &nbsp;&nbsp;&nbsp;Deferred revenue, current portion | 54068 | 53716 |
| &nbsp;&nbsp;&nbsp;Product warranty reserve | 46500 | 46500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 1064101 | 836870 |
| &nbsp;&nbsp;**TERM LOAN PAYABLE, net of current portion and debt issuance costs** | 1044449 | 1058426 |
| &nbsp;&nbsp;**SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs** | 672274 | 681343 |
| &nbsp;&nbsp;**DEFERRED REVENUE, net of current portion** | 7149 | 6151 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 2787973 | 2582790 |
| &nbsp;&nbsp;**COMMITMENTS AND CONTINGENCIES (Note 6)** | **—** |  |
| &nbsp;&nbsp;**STOCKHOLDERS' EQUITY:** |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding | 5934314 | 5934314 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (1983249) | (1830536) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 3951065 | 4103778 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $6739038 | $6686568 |

---

The accompanying notes to the condensed financial statements are an integral part of these condensed financial statements.

**LIFELOC TECHNOLOGIES, INC.**

**Condensed Statements of Profit (Loss) (Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **REVENUES:** | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;Product sales | $2289759 | $2263047 |
| &nbsp;&nbsp;&nbsp;Royalties | 4053 | 5671 |
| &nbsp;&nbsp;&nbsp;Rental income |  | 8316 |
| &nbsp;&nbsp;&nbsp;Total | 2293812 | 2277034 |
| &nbsp;&nbsp;**COST OF SALES** | 1306738 | 1368468 |
| &nbsp;&nbsp;**GROSS PROFIT** | 987074 | 908566 |
| &nbsp;&nbsp;**OPERATING EXPENSES:** |  |  |
| &nbsp;&nbsp;&nbsp;Research, development, and sustaining engineering | 414445 | 469680 |
| &nbsp;&nbsp;&nbsp;Sales and marketing | 313229 | 334556 |
| &nbsp;&nbsp;&nbsp;General and administrative | 387402 | 384878 |
| &nbsp;&nbsp;&nbsp;Total | 1115076 | 1189114 |
| &nbsp;&nbsp;**OPERATING (LOSS)** | (128002) | (280548) |
| &nbsp;&nbsp;**OTHER INCOME (EXPENSE):** |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 6531 | 12357 |
| &nbsp;&nbsp;&nbsp;Interest expense | (31242) | (24495) |
| &nbsp;&nbsp;&nbsp;Total | (24711) | (12138) |
| &nbsp;&nbsp;**NET (LOSS) BEFORE PROVISION FOR TAXES** | (152713) | (292686) |
| &nbsp;&nbsp;**BENEFIT FROM FEDERAL AND STATE INCOME TAXES** |  |  |
| &nbsp;&nbsp;**NET (LOSS)** | $(152713) | $(292686) |
| &nbsp;&nbsp;**NET (LOSS) PER SHARE, BASIC** | $(0.06) | $(0.11) |
| &nbsp;&nbsp;**NET (LOSS) PER SHARE, DILUTED** | $(0.06) | $(0.11) |
| &nbsp;&nbsp;**WEIGHTED AVERAGE SHARES, BASIC** | 2752616 | 2694599 |
| &nbsp;&nbsp;**WEIGHTED AVERAGE SHARES, DILUTED** | 2752616 | 2694599 |

---

The accompanying notes to the condensed financial statements are an integral part of these condensed financial statements.

**LIFELOC TECHNOLOGIES, INC.**

**Condensed Statements of Changes in Stockholders' Equity (Unaudited)**

**For The Three Months Ended March 31, 2026 and 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2026** | **2026** | **2026** | **2026** |
|  | **Common Stock Shares** | **Common Stock Amount** | **Accumulated Deficit** | **Total** |
| &nbsp;&nbsp;Beginning balance | 2752616 | $5934314 | $(1830536) | $4103778 |
| &nbsp;&nbsp;Warrants issued with subordinated debenture |  |  |  |  |
| &nbsp;&nbsp;Issuance of shares from option exercise |  |  |  |  |
| &nbsp;&nbsp;Net (loss) |  |  | (152713) | (152713) |
| &nbsp;&nbsp;Ending balance | 2752616 | $5934314 | $(1983249) | $3951065 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2025** | **2025** |
|  | **Common Stock Shares** | **Common Stock Amount** | **Accumulated Deficit** | **Total** |
| &nbsp;&nbsp;Beginning balance | 2664116 | $5586014 | $639863 | $6225877 |
| &nbsp;&nbsp;Warrants issued with subordinated debenture |  | 12000 |  | 12000 |
| &nbsp;&nbsp;Issuance of shares from option exercise | 88500 | 336300 |  | 336300 |
| &nbsp;&nbsp;Net (loss) |  |  | (292686) | (292686) |
| &nbsp;&nbsp;Ending balance | 2752616 | $5934314 | $347177 | $6281491 |

---

The accompanying notes to the condensed financial statements are an integral part of these condensed financial statements.

**LIFELOC TECHNOLOGIES, INC.**

**Condensed Statements of Cash Flows (Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;Net (loss) | $(152713) | $(292686) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net (loss) to net cash (used in) operating activities- |  |  |
| &nbsp;&nbsp;&nbsp; Depreciation and amortization | 67773 | 102406 |
| &nbsp;&nbsp;&nbsp; Amortization of debt issuance costs | 6051 | 5171 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities- |  |  |
| &nbsp;&nbsp;&nbsp; Accounts receivable | (77961) | (29156) |
| &nbsp;&nbsp;&nbsp; Inventories | (160715) | 54848 |
| &nbsp;&nbsp;&nbsp; Federal and state income taxes receivable |  | (150) |
| &nbsp;&nbsp;&nbsp; Prepaid expenses and other | (38457) | (329643) |
| &nbsp;&nbsp;&nbsp; Deposits and other |  | (562) |
| &nbsp;&nbsp;&nbsp; Accounts payable | 313751 | 342625 |
| &nbsp;&nbsp;&nbsp; Customer and tenant deposits | (15002) | 80395 |
| &nbsp;&nbsp;&nbsp; Accrued expenses | (73442) | (49347) |
| &nbsp;&nbsp;&nbsp; Deferred revenue | 1350 | 15742 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) operating activities | (129365) | (100357) |
| &nbsp;&nbsp;**CASH FLOWS (USED IN) INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of sales and marketing equipment | (5370) |  |
| &nbsp;&nbsp;&nbsp;Purchases of research and development equipment, software and space modifications | (14411) | (18548) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) investing activities | (19781) | (18548) |
| &nbsp;&nbsp;**CASH FLOWS (USED IN) FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments made on term loan | (14093) | (13684) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of subordinated debenture |  | 75000 |
| &nbsp;&nbsp;&nbsp;Principal payments made on subordinated debentures | (13432) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of shares from option exercise |  | 336300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided from (used in) financing activities | (27525) | 397616 |
| &nbsp;&nbsp;**NET INCREASE (DECREASE) IN CASH** | (176671) | 278711 |
| &nbsp;&nbsp;**CASH, BEGINNING OF PERIOD** | 746001 | 1243746 |
| &nbsp;&nbsp;**CASH, END OF PERIOD** | $569330 | $1522457 |
| &nbsp;&nbsp;**SUPPLEMENTAL INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $25191 | $19324 |
| &nbsp;&nbsp;&nbsp;Cash paid for income tax | $— | $150 |
| &nbsp;&nbsp;&nbsp;Non-cash financing and investing activities: warrants issued with subordinated debenture | $— | $12000 |

---

The accompanying notes to the condensed financial statements are an integral part of these condensed financial statements**.** 

 **LIFELOC TECHNOLOGIES, INC.**

**Notes to Condensed Financial Statements (Unaudited)**

**March 31, 2026 and 2025**

1. <u>ORGANIZATION AND NATURE OF BUSINESS</u>

Lifeloc Technologies, Inc. ("Lifeloc" or the "Company", "Us", "Our", or "We") is a Colorado-based developer, manufacturer and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education. We design, produce and sell fuel-cell based breath alcohol testing equipment. We compete in all major segments of the breath alcohol testing instrument market, including law enforcement, workplace, corrections, original equipment manufacturing ("OEM") and consumer markets. In addition, we offer a line of supplies, accessories, services, and training to support customers' alcohol testing programs. We sell globally through distributors as well as directly to users.

We define our business as providing "near and remote sensing and monitoring" products and solutions. Today, the majority of our revenues are derived from products and services for alcohol detection and measurement. We remain committed to growing our breath alcohol testing business. In the future, we anticipate the commercialization of new sensing and measurement products that may allow Lifeloc to successfully expand our business into new growth areas where we do not presently compete or where no satisfactory product solutions exist today.

Lifeloc incorporated in Colorado in December 1983. We filed a registration statement on Form 10 with the Securities and Exchange Commission, which became effective on May 31, 2011. Our fiscal year end is December 31. Our principal executive offices are located at 12441 West 49th Avenue, Unit 4, Wheat Ridge, Colorado 80033-3338. Our telephone number is (303) 431-9500. Our websites are www.lifeloc.com and www.lifelocuniversity.com.

2. <u>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND PROCESSES</u>

<u>Basis of Presentation</u>. These statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States ("GAAP") for interim financial information. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to financial statements included in Lifeloc's Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of only normal recurring adjustments necessary for a fair statement of the financial position as of March 31, 2026 and December 31, 2025, and the results of operations and cash flows for the three months ended March 31, 2026 and March 31, 2025. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for a full year. The Company's 2025 Annual Report on Form 10-K includes certain definitions and a summary of significant accounting policies and should be read in conjunction with this Form 10-Q.

<u>Inventories.</u> Inventories are stated at the lower of standard average cost or net realizable value. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated net realizable value after cost to sell, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At March 31, 2026 and December 31, 2025, inventory consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| &nbsp;&nbsp;Raw materials & deposits | $2641862 | $2576194 |
| &nbsp;&nbsp;Work-in-process | 6541 | 19451 |
| &nbsp;&nbsp;Finished goods | 585082 | 477125 |
| &nbsp;&nbsp;Total gross inventories | 3233485 | 3072770 |
| &nbsp;&nbsp;Less reserve for obsolescence | (439156) | (439156) |
| &nbsp;&nbsp;Total net inventories | $2794329 | $2633614 |

---

<u>Income Taxes.</u> We account for income taxes under the provisions of Accounting Standards Codification ("ASC") Topic 740, *Accounting for Income Taxes* ("ASC 740"). ASC 740 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. ASC 740 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. We estimate that our current effective tax rate to be 0% for 2026.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements, uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

<u>Revenue Recognition.</u>

We recognize revenue in accordance with ASC Topic 606 using the five-step model: identifying the contract with a customer, identifying performance obligations, determining and allocating the transaction price, and recognizing revenue when performance obligations are satisfied.

Our contracts generally contain a single performance obligation to deliver products or supplies. Transaction prices are fixed and determinable at order acceptance. Revenue is recognized at a point in time when control transfers to the customer, typically upon shipment when title has passed.

For product development arrangements, revenue is recognized upon achievement of contractual milestones. Sales to stocking distributors are recognized when control transfers and there are no rights of return other than standard warranty provisions. We generally have no significant post-delivery obligations other than standard warranties.

The sales of licenses to our training courses are recognized as revenue at the time of sale. Training and certification revenues are recognized at the time the training and certification occurs. Data recording revenue is recognized based on each day's usage of enrolled devices.

Revenues arising from extended warranty contracts are booked as sales over their life on a straight-line basis. We have discontinued arranging for customer financing and leasing through unrelated third parties and instead are providing for customer financing and leasing ourselves, which we recognize as revenue over the applicable lease term. Occasionally, we rent used equipment to customers, and in those cases, we recognize the revenues as they are earned over the life of the contract.

Royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable and collectability is reasonably assured.

On occasion we receive customer deposits for future product orders and product developments. Customer deposits are initially recorded as a liability and recognized as revenue when the product is shipped and title has passed to the customer, or when agreed milestones are met in the case of product developments.

<u>Deferred Revenue.</u> Deferred revenues arise from service contracts and from direct training revenue. Revenues from service contracts are recognized on a straight-line basis over the life of the contract, generally one year, and are included in product revenue in our statements of income (loss). However, there are occasions when they are written for longer terms up to four years. The revenues from that portion of the contract that extend beyond one year are shown in our balance sheets as long term. Deferred revenues also result from direct training revenue that needs to be scheduled based on the customer's and Lifeloc's availability. Revenue is recognized when training is complete and is included in product sales in our statements of income. All direct training is for less than one year and all deferred revenues from this source are shown in our balance sheets as short term.

<u>Recently Issued Accounting Pronouncements:</u> In November 2024, the FASB issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company's annual periods for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating the ASU to determine its impact on our consolidated financial statements and disclosures.

The Company does not believe that issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's financial statements.

3. <u>BASIC AND DILUTED (LOSS) PER COMMON SHARE</u>

We report both basic and diluted net income or loss per common share. Basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options and warrants to purchase shares where the exercise price was greater than the average market price of common shares for the period. For the three months ended March 31, 2026, options to purchase 15,000 shares and warrants to purchase 68,750 shares were excluded from the computation of diluted net loss per share, and for the three months ended March 31, 2025, options to purchase 33,500 shares and warrants to purchase 68,750 shares were excluded from the computation of diluted net loss per share, because their effect during those periods would have been antidilutive.

The following table presents the calculation of basic and diluted net (loss) per common share for three months ended March 31, 2026 and March 31, 2025.

---

| | | |
|:---|:---|:---|
|  | **2026** | **2025** |
| &nbsp;&nbsp;Net (loss) | $(152713) | $(292686) |
| &nbsp;&nbsp;Weighted average shares-basic | 2752616 | 2694599 |
| &nbsp;&nbsp;Effect of dilutive potential common shares |  |  |
| &nbsp;&nbsp;Weighted average shares-diluted | 2752616 | 2694599 |
| &nbsp;&nbsp;Net (loss) per share-basic | $(0.06) | $(0.11) |
| &nbsp;&nbsp;Net (loss) per share-diluted | $(0.06) | $(0.11) |

---

4. <u>STOCKHOLDERS' EQUITY</u>

In February 2025, options to purchase 88,500 shares of our common stock, originally granted as incentive stock options pursuant to our 2013 Stock Option Plan, were assigned by the option holders to EDCO Partners LLLP and a third director. The Board of Directors approved the assignments and waived the non-transferability provisions of the applicable option agreements and the Plan solely to permit such assignments. Upon assignment, the options ceased to qualify as incentive stock options and were reclassified as nonqualified stock options for all tax, accounting, and compliance purposes. EDCO Partners LLLP, of which our CFO and board chairman is the general partner, and a third director then exercised the assigned options at a price of $3.80 per share for total proceeds of $336,300 to the Company. There was no intrinsic value on the exercised options. At March 31, 2026, 15,000 options remained outstanding with a weighted average life of 0.33 years. All 15,000 of these options were fully vested. The options outstanding at March 31, 2026 had an intrinsic value of $0.

At March 31, 2026, there were 68,750 warrants outstanding, all with an exercise price of $4.50 and all expiring December 31, 2030.

5. <u>DEBT</u>

<u>Subordinated Debentures Payable</u>. On December 31, 2024, we issued a $750,000 unsecured debenture that is subordinated to the Company's existing secured indebtedness, which is collateralized by a lien on substantially all of the Company's assets. The debenture bears interest only at 8.25% payable quarterly in 2025, with monthly payments of $9,199 including principal and interest at 8.25% commencing on January 31, 2026. A balloon payment of $451,012 is due in full on December 31, 2030.

In consideration of the lender providing the financing, the Company issued warrants which entitle the holder to purchase 62,500 shares of our common stock at $4.50 per share.

On March 1, 2025, we issued a $75,000 unsecured debenture that is subordinated to the Company's existing secured indebtedness, which is collateralized by a lien on substantially all of the Company's assets. The debenture bears interest only at 8.25% payable quarterly in 2025. A balloon payment of $45,707 is due in full on December 31, 2030. In consideration of the lender providing this financing, the Company issued warrants which entitle the holder to purchase 6,250 shares of our common stock at $4.50 per share. If the debenture is paid in full on or before December 31, 2029, the warrants will have a remaining life of 58 months from March 1, 2025.

The factors used to calculate the estimated value of these warrants, and the resulting fair value, were as follows.

---

| | |
|:---|:---|
| Stock price | $2.75 |
| Exercise price per share | $4.50 |
| Original term (months) | 70 |
| Volatility | 116.58% |
| Annual rate of quarterly dividends |  |
| Risk free interest rate | 4.38% |

---

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Expiration of Warrants if Debenture is Paid on December 31, 2030** | &nbsp;&nbsp;**Expiration of Warrants if Debenture is Paid on December 31, 2029** |
| Warrants issued December 31, 2024 | &nbsp;&nbsp;December 31, 2030 | &nbsp;&nbsp;December 31, 2029 |
| Warrants issued March 1, 2025 | &nbsp;&nbsp;December 31, 2030 | &nbsp;&nbsp;December 31, 2029 |

---

Our minimum future principal payments on all of the above subordinated debentures are as follows:

---

| | |
|:---|:---|
| March 31, 2027 | $56579 |
| March 31, 2028 | 61428 |
| March 31, 2029 | 66692 |
| March 31, 2030 | 72407 |
| December 31, 2030 | 554461 |
| Total | 811567 |
| Less debt issuance cost | (104771) |
| Net subordinated debenture payable | 706796 |
| Less current portion | (34522) |
| Long term portion | $672274 |

---

<u>Term Loan Payable</u>. The term loan is secured by a first mortgage on our building and is payable in 119 equal monthly installments of $7,453 commencing October 30 2021, including principal and interest at 2.95% based on a 360 day year, plus a final payment of $806,750 (excluding interest) on September 30, 2031. Our minimum future principal payments on this term loan, by year, are as follows:

---

| | |
|:---|:---|
| March 31, 2027 | 57421 |
| March 31, 2028 | 59138 |
| March 31, 2029 | 60907 |
| March 31, 2030 | 62728 |
| March 31, 2031 | 64604 |
| September 30, 2031 | 806750 |
| Total | 1111548 |
| Less debt issuance cost | (11828) |
| Net term loan payable | 1099720 |
| Less current portion | (55271) |
| Long term portion | $1044449 |

---

6. <u>COMMITMENTS AND CONTINGENCIES</u>

<u>Employee Severance Benefits</u>. Our obligation with respect to employee severance benefits is minimized by the "at will" nature of the employee relationships. As of March 31, 2026, we had no obligation with respect to contingent severance benefit obligations other than the Company's obligations under the employment agreement with its chief executive officer, Dr. Wayne Willkomm. In the event that Dr. Willkomm's employment is terminated by the Company without Cause (including through a decision by the Company not to renew the employment agreement) or by Dr. Willkomm with Good Reason (as each are defined in the employment agreement), Dr. Willkomm will be eligible, upon satisfaction of certain conditions, for severance equal to two months of salary continuation plus 12 months of health insurance continuation.

<u>Contractual Commitments and Purchase Orders</u>. Contractual commitments under development agreements and outstanding purchase orders issued to vendors in the ordinary course of business totaled $1,897,421 at March 31, 2026.

<u>Regulatory Commitments</u>. We are subject to certain regulations of the United States Department of Transportation and various state departments of transportation. We believe that we are in substantial compliance with all known applicable regulations.

7. <u>LEGAL PROCEEDINGS</u>

We were not involved or party to any legal proceedings at March 31, 2026 or December 31, 2025, and therefore made no accruals for legal proceedings in either 2026 or 2025.

8. <u>BUSINESS SEGMENT</u>

Operating segments are defined under ASU 2023-07, Segment Reporting (Topic 280), as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker ("CODM"), in this case, the Company's Chief Executive Officer. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results on a consolidated basis based on net income (losses). On this basis, the CODM has determined the Company operates in one operating and reportable segment: the development, manufacture, and sale of portable hand-held breathalyzers and drug screening products, and related accessories, supplies, education, and training, together with royalties from development contracts with original equipment manufacturers. Until June 30, 2025, we had a second segment consisting of a rental of a portion of our building. That segment was eliminated following the tenant lease not being renewed on June 30, 2025.

9. <u>SUBSEQUENT EVENTS</u>

We evaluated all of our activity and concluded that no subsequent events have occurred through the date of filing that would require recognition in our financial statements or disclosure in the notes to our financial statements, except as follows.

On May 4, 2026 the Company entered into a loan agreement for $500,000 with its CFO and Board Chairman. The loan bears interest at 10.5% per annum, with interest only payments due monthly from May 31, 2026 through December 31, 2026. Beginning January 31, 2027, the loan will be paid over five years with equal monthly payments of principal and interest of $10,747, at which time the note will be paid in full. The interest rate is subject to adjustment based on changes in the prime rate. If the prime rate, as published in the Eastern edition of ***The Wall Street Journal*** on the last business day of any calendar quarter beginning June 30, 2026 (the "Published Rate"), exceeds 6.75%, the interest rate on the note will increase for the remaining term by the amount of such excess. Any subsequent increases in the Published Rate will result in corresponding increases in the interest rate. The loan is secured by substantially all assets of the Company, including its building, and is subordinate to the prior perfected security interest held by Citywide Banks.

**ITEM 2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following is a discussion of our financial condition and results of operations, and should be read in conjunction with our financial statements and the related notes included elsewhere in this Form 10-Q. Certain statements contained in this section are not historical facts, including statements about our strategies and expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market and industry segment growth, and return on investments in products and markets. These statements are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), and we intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in these statutes. You can identify forward-looking statements by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "seeks," "intends," "plans" or "anticipates" or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. Such statements involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements in this section are based on information available to us on the date of this document, and we assume no obligation to update such forward looking statements. Readers of this Form 10-Q are strongly encouraged to review the section titled "Risk Factors" in our December 31, 2025 Form 10-K.*

**Overview**

Lifeloc Technologies, Inc., a Colorado corporation ("Lifeloc" or the "Company"), is a leading developer, manufacturer and marketer of portable hand-held and fixed station breathalyzers, now focused on expanding our offerings into technologies for the detection of drugs of abuse.

We began our alcohol breath testing product line in 1989 with the PBA3000, later replaced by the Phoenix® Classic in 1998, and subsequently by the FC Series and Workplace Series. Our FC Series, launched in 2001, is designed for domestic and international law enforcement and corrections markets and is approved by the U.S. Department of Transportation (DOT) for evidential use. Our Workplace Series, including the EV30 and Phoenix® 6.0 released in 2005 and 2006, also received DOT approval for federally regulated workplace testing. We have since introduced a range of innovations such as Bluetooth connectivity, passive screening devices like the FC5 and Sentinel™ stations, and the EASYCAL® automatic calibration systems.

We compete in all major segments of the portable breath alcohol testing instrument market, including law enforcement, workplace, corrections, and original equipment manufacturing ("OEM") markets. In addition, we offer a line of supplies, accessories, services, and training to support customers' alcohol testing programs. We sell globally through distributors as well as directly to users.

In August 2016, we entered into a patent license agreement with Sandia Corporation pursuant to which we acquired the exclusive rights to develop, manufacture, and market Sandia's patented SpinDx™ technology for the detection of drugs of abuse. The SpinDetect™ platform uses a centrifugal disk with microfluidic flow paths to conduct multiple quantitative drug assays on a single small sample, delivering on-site results in minutes at a fraction of the cost of conventional laboratory testing. The technology is capable of detecting very low concentrations of high-abuse drugs such as fentanyl, cocaine, and delta-9-THC. Importantly, SpinDetect™ can isolate psychoactive delta-9-THC from its inactive metabolites — a capability that existing devices lack, and that we believe will enable more accurate assessments of marijuana impairment. Under the license agreement, Sandia retains ownership of the foundational patents, while patentable enhancements developed by Lifeloc belong solely to us. Our first utility patent application covering improvements to the system was filed in February 2024.

We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. We are initiating beta testing of the oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component optimization underway under a signed beta-testing agreement. The initial commercial product is expected to measure delta-9-THC, followed by a multi-drug panel release. We anticipate a commercial launch in 2026, with subsequent expansion into additional drug panels and sample types, including blood and breath — the latter integrated with our LX9 breathalyzer. The SpinDetect™ reader is designed to accept multiple disk formats, which may also enable future applications beyond drug testing, such as detection of food-safety markers and environmental contaminants; these applications would require additional research, regulatory clearances, and potential expansion of our existing license rights. Continued progress toward commercialization is dependent on timely access to capital to support fabrication, validation, regulatory preparation, and market introduction.

We place strong emphasis on high-quality training as a key component of our testing business. Initially offering in-person instruction through Master Trainers, we expanded into online modules, webcam-based training, and in 2011 launched Lifeloc University, a learning management system (LMS) that was later enhanced for mobile use and regulatory updates. Our 2014 acquisition of Superior Training Solutions (STS) added further online training assets and customers that were contributed to Lifeloc University, which now serves as our unified, modern training platform.

We own our corporate headquarters in Wheat Ridge, Colorado, occupying all of the space ourselves after June 30, 2025. Our tenant's lease expired in June 2025, at which time we expanded into the full space. Additionally, we continue to pursue acquisitions aligned with our mission to deliver near and remote sensing and monitoring solutions, aiming to strengthen own position in existing markets and facilitate entry into new ones.

**Outlook**

*Installed Base of Breathalyzers*. We believe the installed base of our breathalyzers will increase as the inherent risks associated with drinking while driving or while working in safety sensitive jobs become more widely acknowledged and as our network of distributors and our direct sales force grows. We believe that increased marketing efforts, the introduction of new products and the expansion of our sales network may provide the basis for increased sales and continuing profitable operations. However, these measures, or any others that we may adopt or determine not to adopt, may not result in either increased sales or continuing profitable operations.

*Possibility of Operating Losses.* Over many of the past several years we have operated profitably; however, prior to that, and in 2021 through 2025, we incurred operating losses. Those operating losses are continuing in 2026 and we expect them to continue as we continue to work toward the commercialization of SpinDetect™. There is no assurance that we will not incur operating losses in any given quarter or year in the future.

*Sales Growth*. We expect to increase sales in the U.S. and worldwide as our network of direct customers and distributors grows and becomes more proficient and expands the number of new accounts. Our growth efforts have focused on expanding our global reach and broadening our product offering in alcohol and drug detection. Orders for all of our products are on an intermittent purchase order basis and there is no assurance they will continue at any given rate, or that orders will repeat.

*Sales and Marketing Expenses.* We continue our efforts to expand our domestic and international distribution capability, and we believe that sales and marketing expenses will need to be maintained at a healthy level in order to do so. Sales and marketing expenses are expected to increase as we increase our direct sales representatives and marketing efforts.

*Research and Development Expenses*. We expect to begin to reduce our research and development expenses in 2026 as we complete development of our new product line.

**Results of Operations**

***For the three months ended March 31, 2026 compared to the three months ended March 31, 2025****.*

 

We work diligently to maintain reduced costs where possible, although inflation is taking a toll, increasing the cost of raw materials, labor, and freight. We continued and intensified our new product development efforts while maintaining the high level of customer service that has led to an excellent reputation for outstanding customer service. With the introduction of new products, we believe Lifeloc will again be profitable.

 

*Net sales.*

Our product sales for the three months ended March 31, 2026 were $2,289,759, an increase of 1% from $2,263,047 for the same period a year ago. This increase results from acceleration of several larger orders that may reflect customers' current availability of funds. In addition, the continuing inflationary pressure outlook on customers' budgets may also have played a role. When royalties of $4,053 and rental income of $0 are included, total revenues of $2,293,812 increased by $16,778, or 1%, for the three months ended March 31, 2026 when compared to the same three months a year ago. Rental income was discontinued after June 30, 2025, and royalties decreased by $1,618 due to a decrease in sales by royalty-paying customers.

*Gross profit.*

Gross profit for the three months ended March 31, 2026 of $987,074 represented an increase of 9% from total gross profit of $908,566 for the three months ended March 31, 2025, primarily as a result of higher product sales. Cost of product sales decreased from $1,363,805 in the three months ended March 31, 2025 to $1,306,738 in the same period in 2026, a decrease of $57,067 (4%). Gross profit margin on products increased to 43% in the three months ended March 31, 2026 from 40% in the three months ended March 31, 2025 primarily as a result of the higher sales and product mix.

*Research, development and sustaining engineering expenses.*

Research, development and sustaining engineering expenses continued at the high level of $414,445, or 18% of product sales, for the three months ended March 31, 2026, representing a decrease of $55,235 (12%) over the $469,680 in the same period a year ago. This decrease resulted primarily from a lull in payments to outside contractors needed for continuing design work related to SpinDetect™.

*Sales and marketing expenses.*

Sales and marketing expenses of $313,229 for the three months ended March 31, 2026 were down by $21,327 (or 6%) from the $334,556 spent in the same period a year ago as a result of across the board efforts to lower expenses.

*General and administrative expenses.*

General and administrative expenses of $387,402 for the three months ended March 31, 2026 versus $384,878 for the three months ended March 31, 2025 were relatively unchanged.

*Other income (expense).*

Interest income decreased from $12,357 a year ago to $6,531 in 2026 as a result of less funds available at the beginning of the period. Interest expense of $31,242 in the three months ended March 31, 2026 was up from $24,495 in the previous year as a result of the increase in subordinated debentures outstanding in the 2026 quarter vs. less in the same quarter a year ago. The total increase of $12,573 from $12,138 of other expense (net) in the period ended March 31, 2025 to total other expense (net) of $24,711 in the current quarter is expected to continue in future quarters due to the increase in borrowings.

*Net income (loss).*

We realized a net (loss) of ($152,713) for the three months ended March 31, 2026 compared to a net (loss) of ($292,686) for the three months ended March 31, 2025. This decrease of $139,973 (48%) was the result of the changes in gross profit, operating expenses and other income discussed above. The benefit from taxes in the three months ended March 31, 2026 was $0 which was the same amount in the same period a year ago.

*Trends and Uncertainties That May Affect Future Results*

 

Revenues in the first three months of 2026 were slightly higher compared to revenues during the same period in 2025. We believe that continued increased sales efforts may result in modestly improved revenues in 2026 and beyond with the anticipated availability of SpinDetect™. Revenues in 2026 may be similar to revenues in 2025. Inflationary pressures have affected our business in a number of ways, including increasing the cost of raw materials, labor, and freight. Our actions to mitigate the impact of inflation, including pre-ordering components in higher than usual quantities, sourcing new vendors and increasing prices have been somewhat successful.

We expect our quarter-to-quarter revenue fluctuations to continue, due to the unpredictable timing of large orders from customers and the size of those orders in relation to total revenues. Going forward, we intend to focus our development efforts on products we believe offer the best prospects to increase our intermediate and near-term revenues, with particular emphasis on completing SpinDetect™.

Our operating plan for the remainder of 2026 is focused on growing sales, increasing gross profits, and continuing research and development efforts on new products, including SpinDetect™, for long-term growth. We cannot predict with certainty the expected sales, gross profit, net income or loss, or usage of cash and cash equivalents for 2026. However, we believe that cash resources will be sufficient to fund our operations for the next twelve months under our current operating plan. If we are unable to manage the business operations in line with our budget expectations, it could have a material adverse effect on business viability, financial position, results of operations and cash flows. Further, if we are not successful in sustaining profitability and remaining at least cash flow break-even, additional borrowings or capital may be required to maintain ongoing operations.

*Interest expense*.

In connection with the financing of our building purchase on October 31, 2014 we obtained a 10-year term loan from Bank of America in an initial principal amount of $1,581,106 bearing interest at 4.45% per annum (which was decreased to 4% in 2016) and secured by a first-priority mortgage in the acquired property. The Bank of America loan was paid on September 30, 2021 with proceeds from a new term loan from Citywide Banks, also secured by a first-priority mortgage on the property, in the principal amount of $1,350,000. The new loan is payable in monthly installments of $7,453, with interest at 2.95% and a maturity date of September 30, 2031.

On December 31, 2024 we issued an unsecured $750,000 subordinated debenture bearing interest at 8.25%, including 62,500 warrants exercisable on or before December 31, 2030 into 62,500 shares of our common stock at a price of $4.50 per share. On March 1, 2025 we issued an unsecured $75,000 subordinated debenture bearing interest at 8.25%, including 6,250 warrants exercisable on or before December 31, 2030 into 6,250 shares of our common stock at a price of $4.50 per share. Using the Black Scholes model, the fair market value of these warrants resulted in deferred financing cost of $132,000, which is included in our balance sheet at March 31, 2026 at $126,829 after amortization in the three months ending March 31, 2026 of $5,171, and which resulted in an increase to capital of $120,000 on December 31, 2024 and $12,000 on March 1, 2025. The interest of 8.25% was paid in quarterly increments in 2025, and will be included in monthly payments of $10,119 including principal in 2026.

**Liquidity and Capital Resources**

We compete in a highly technical, very competitive and, in most cases, price driven alcohol testing marketplace, where products can take years to develop and introduce to distributors and end users. Furthermore, manufacturing, marketing and distribution activities are regulated by the DOT and other regulatory bodies that, while intended to enhance the ultimate quality and functionality of products produced, can contribute to the cost and time needed to maintain existing products and develop and introduce new products.

Except for normal operating contractual commitments and purchase orders, we do not have any material contractual commitments requiring settlement in the future.

We have traditionally funded working capital needs through product sales and close management of working capital components of our business. Historically, we have also received cash from private offerings of our common stock, warrants to purchase shares of our common stock, and notes. In July, 2024 we completed a private placement of 210,000 shares of our common stock at $3.80 per share for a total raise of $798,000 with a related party. On December 31, 2024, we completed the issuance of a six year subordinated debenture for $750,000 with a third party. On March 1, 2025, we completed the issuance of a 70-month subordinated debenture for $75,000 with a third party. In our earlier years, we incurred quarter to quarter operating losses to develop current product applications, utilizing a number of proprietary and patent-pending technologies. Between 2002 and 2020, we were consistently profitable, due to stabilization and then growth in our core breathalyzer products. Our recent net losses in 2024 and 2025 reflect a deliberate investment in the development of our SpinDetect™ platform rather than a deterioration of our core breathalyzer business, which has remained stable. We believe our core product and services business, at current revenue levels, is capable of supporting ongoing operations on a cost-reduced basis. We intend to continue managing costs carefully while advancing SpinDetect™ toward its anticipated commercial launch later in 2026. If the development or market acceptance of SpinDetect™ takes longer than expected, or if we require additional capital to support commercialization, we may seek additional financing through equity or debt offerings.

During the three months ended March 31, 2026, net cash used in operating activities was $129,365, reflecting the net loss partially offset by non-cash charges and working capital changes. Net cash used in investing activities was $19,781, primarily for equipment purchases. Net cash used in financing activities was $27,525, consisting of scheduled principal payments on our term loan. Subsequent to March 31, 2026, we obtained additional debt financing from a related party to fund the continued development of SpinDetect™.

As of March 31, 2026, cash and cash equivalents were $569,330, trade accounts receivable were $850,341 and current liabilities were $1,064,101 resulting in net liquid assets of $355,570. We believe our core breathalyzer business has remained fundamentally sound and, together with the anticipated commercialization of SpinDetect™, provides a reasonable basis for a return to profitability. However, if revenues from our core business do not grow as expected, if the commercialization of SpinDetect™ is delayed or requires more capital than anticipated, or if general economic conditions deteriorate, we may be required to seek additional sources of capital and/or to implement further cost reduction measures, as necessary.

Equipment expenditures during the three months ended March 31, 2026 consisted of SpinDetect™ related equipment of $14,411 compared to $18,548 in the first three months of 2025, and $5,370 in office equipment versus $0 in 2025. No patent application costs were incurred during either period. As development of SpinDetect™ progresses, and as normal wear and tear of equipment occurs, we expect to incur outlays for equipment and patent filings in 2026 and beyond.

We generally provide a standard one-year limited warranty on materials and workmanship to our customers. We provide for estimated warranty costs at the time product revenue is recognized. Warranty costs are included as a component of cost of goods sold in the accompanying statements of operations. For the three months ended March 31, 2026 and 2025, warranty costs were not deemed significant.

**Critical Accounting Policies and Estimates**

There have been no material changes to the Company's critical accounting policies and estimates from those disclosed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

**ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

**ITEM 4 – CONTROLS AND PROCEDURES**

(a)&nbsp;&nbsp;&nbsp;&nbsp; Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.

(b)&nbsp;&nbsp;&nbsp;&nbsp; Changes in Internal Control over Financial Reporting

There were no significant changes in our internal controls over financial reporting during the period ended March 31, 2026 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

**Limitations on the Effectiveness of Controls**

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Our management, including our Chief Executive Officer and our Chief Financial Officer, do not expect that the Company's disclosure controls will prevent or detect all errors and all fraud. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

**PART II. OTHER INFORMATION**

**ITEM 1 – LEGAL PROCEEDINGS**

We may be involved from time to time in litigation, negotiation and settlement matters that may have a material effect on our operations or finances. We are not aware of any pending or threatened litigation against us or our officers or directors in their capacity as such that could have a material impact on our operations or finances.

**ITEM 1A – RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in ''Risk Factors'' in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition and/or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

*We have increased our reliance on related-party financing, which may present conflicts of interest and limit our financial flexibility.*

On May 4, 2026, we entered into a loan agreement with our CFO and Board Chairman. The loan is secured by substantially all of our assets and is subordinate to the prior perfected security interest held by our senior lender. As a result, substantially all of our assets are now pledged as collateral to multiple lenders, which may limit our ability to obtain additional financing or to dispose of assets without lender consent. The interest rate on the loan is subject to upward adjustment based on changes in the prime rate, which could increase our debt service costs in a rising rate environment. In addition, because the lender is also our CFO and Board Chairman, the terms of the loan were not negotiated on an arm's-length basis with an unrelated third party, and the lender's dual role could present conflicts of interest in connection with future decisions regarding the loan, including any amendments, extensions, or enforcement actions.

**ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

In February 2025, options to purchase 88,500 shares of our common stock, originally granted as incentive stock options pursuant to our 2013 Stock Option Plan, were assigned by the option holders to EDCO Partners LLLP and a third director. The Board of Directors approved the assignments and waived the non-transferability provisions of the applicable option agreements and the Plan solely to permit such assignments. Upon assignment, the options ceased to qualify as incentive stock options and were reclassified as nonqualified stock options for all tax, accounting, and compliance purposes. EDCO Partners LLLP, of which our CFO and board chairman is the general partner, and a third director then exercised the assigned options at a price of $3.80 per share for total proceeds of $336,300 to the Company. The shares were issued to EDCO Partners LLLP and the third director in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering.

 **ITEM 3 – DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4 – MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5 – OTHER INFORMATION**

During the quarter ended March 31, 2026, no director or officer of the Company adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(a) of Regulation S-K.

**ITEM 6 – EXHIBITS**

The following exhibits are filed with this report on Form 10-Q or are incorporated by reference:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit No.** | <br>**Description of Exhibit** | **Form** | **Date Filed** | **Number** | <br>**Herewith** |
| 10.1 | [Promissory Note, dated May 1, 2026, by Lifeloc Technologies, Inc. in favor of Vern Kornelsen](http://www.sec.gov/Archives/edgar/data/1493137/000107997326000624/ex10x1.htm) | 8-K | 5/8/26 |  |  |
| 31.1 | [Certification of Principal Executive Officer Pursuant To Section 302 Of The Sarbanes—Oxley Act Of 2002](ex31x1.htm) |  |  |  | X |
| 31.2 | [Certification of Principal Financial Officer Pursuant To Section 302 Of The Sarbanes—Oxley Act Of 2002](ex31x2.htm) |  |  |  | X |
| 32.1 | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x1.htm) |  |  |  | X |
| 32.2 | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x2.htm) |  |  |  | X |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  | X |

---

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | LIFELOC TECHNOLOGIES, INC. |
| May 14, 2026 | &nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Wayne R. Willkomm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
| Date |  | Wayne R. Willkomm, Ph.D. |
|  |  | President and Chief Executive Officer<br> (Principal Executive Officer) |
| May 14, 2026&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; | &nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Michelle Heim&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
| Date |  | Michelle Heim<br> Controller<br> (Principal Accounting Officer) |

---

**Exhibit Index**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit No.** | <br>**Description of Exhibit** | **Form** | **Date Filed** | **Number** | <br>**Herewith** |
| 10.1 | [Promissory Note, dated May 1, 2026, by Lifeloc Technologies, Inc. in favor of Vern Kornelsen](http://www.sec.gov/Archives/edgar/data/1493137/000107997326000624/ex10x1.htm) | 8-K | 5/8/26 |  |  |
| 31.1 | [Certification of Principal Executive Officer Pursuant To Section 302 Of The Sarbanes—Oxley Act Of 2002](ex31x1.htm) |  |  |  | X |
| 31.2 | [Certification of Principal Financial Officer Pursuant To Section 302 Of The Sarbanes—Oxley Act Of 2002](ex31x2.htm) |  |  |  | X |
| 32.1 | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x1.htm) |  |  |  | X |
| 32.2 | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32x2.htm) |  |  |  | X |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  | X |

---

## Exhibit 31.1

Exhibit 31.1

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Wayne R. Willkomm, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form 10-Q of Lifeloc Technologies, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 14, 2026

---

| |
|:---|
| /s/ Wayne R. Willkomm |
| Wayne R. Willkomm, Ph.D. |
| Chief Executive Officer<br> (Principal Executive Officer) |

---

## Exhibit 31.2

Exhibit 31.2

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER** 

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Vern D. Kornelsen, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form 10-Q of Lifeloc Technologies, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: May 14, 2026

---

| |
|:---|
| /s/ Vern D. Kornelsen |
| Vern D. Kornelsen |
| Chief Financial Officer<br> (Principal Financial Officer) |

---

## Exhibit 32.1

Exhibit 32.1

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Wayne R. Willkomm, Chief Executive Officer of Lifeloc Technologies, Inc. (the "Company"), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

● the Quarterly Report on Form 10-Q of the Company for the period ended
 March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
 of 1934 (15 U.S.C. 78m or 78o(d)); and

● the information contained in the Report fairly presents, in all material
 respects, the financial condition and results of operations of the Company for the period covered by the Report.

Dated: May 14, 2026

---

| |
|:---|
| /s/ Wayne R. Willkomm |
| Wayne R. Willkomm, Ph.D.<br> Chief Executive Officer<br> (Principal Executive Officer) |

---

## Exhibit 32.2

Exhibit 32.2

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Vern D. Kornelsen, Chief Financial Officer of Lifeloc Technologies, Inc. (the "Company"), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

● the Quarterly Report on Form 10-Q of the Company for the period ended
 March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
 of 1934 (15 U.S.C. 78m or 78o(d)); and

● the information contained in the Report fairly presents, in all material
 respects, the financial condition and results of operations of the Company for the period covered by the Report.

Dated: May 14, 2026

---

| |
|:---|
| /s/ Vern D. Kornelsen |
| Vern D. Kornelsen |
| Chief Financial Officer<br> (Principal Financial Officer) |

---